These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 3137708)

  • 1. Antibody-enhanced thrombolysis: capture of tissue plasminogen activator by a bispecific antibody and direct targeting by an antifibrin-tissue plasminogen activator conjugate in vivo.
    Runge MS; Bode C; Matsueda GR; Haber E
    Trans Assoc Am Physicians; 1987; 100():250-5. PubMed ID: 3137708
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.
    Bode C; Runge MS; Branscomb EE; Newell JB; Matsueda GR; Haber E
    J Biol Chem; 1989 Jan; 264(2):944-8. PubMed ID: 2492021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator.
    Branscomb EE; Runge MS; Savard CE; Adams KM; Matsueda GR; Haber E
    Thromb Haemost; 1990 Oct; 64(2):260-6. PubMed ID: 2125375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.
    Runge MS; Bode C; Matsueda GR; Haber E
    Biochemistry; 1988 Feb; 27(4):1153-7. PubMed ID: 3130094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fibrin specific monoclonal antibody which interferes with the fibrinolytic effect of tissue plasminogen activator.
    Gargan PE; Ploplis VA; Scheu JD
    Thromb Haemost; 1988 Jun; 59(3):426-31. PubMed ID: 3142080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.
    Runge MS; Bode C; Matsueda GR; Haber E
    Proc Natl Acad Sci U S A; 1987 Nov; 84(21):7659-62. PubMed ID: 3118374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation.
    Ruef J; Nordt TK; Peter K; Runge MS; Kübler W; Bode C
    Thromb Haemost; 1999 Jul; 82(1):109-14. PubMed ID: 10456463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanism of thrombolytic enzymes].
    Matsuo O
    Rinsho Ketsueki; 1993 Apr; 34(4):395-402. PubMed ID: 8510325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of fibrinolysis by bispecific monoclonal antibodies reactive to fibrin and plasminogen activators.
    Kurokawa T; Iwasa S; Kakinuma A
    Thromb Res Suppl; 1990; 10():83-9. PubMed ID: 2107601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation.
    Lijnen HR; Soria J; Soria C; Collen D; Caen JP
    Thromb Haemost; 1984 Feb; 51(1):108-9. PubMed ID: 6539000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-directed fibrinolysis: a bispecific (Fab')2 that binds to fibrin and tissue plasminogen activator.
    Runge MS; Bode C; Savard CE; Matsueda GR; Haber E
    Bioconjug Chem; 1990; 1(4):274-7. PubMed ID: 2129015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue-type plasminogen activator and fibrin monomers synergistically cause platelet dysfunction during retransfusion of shed blood after cardiopulmonary bypass.
    de Haan J; Schönberger J; Haan J; van Oeveren W; Eijgelaar A
    J Thorac Cardiovasc Surg; 1993 Dec; 106(6):1017-23. PubMed ID: 8246533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
    Doolittle RF; Pandi L
    Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potentiating effect of platelet on plasminogen activation by tissue plasminogen activator.
    Deguchi K; Murashima S; Shirakawa S; Soria C; Soria J; Dunn F; Tobelem G
    Thromb Res; 1985 Dec; 40(6):853-61. PubMed ID: 3937289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelets and plasminogen activation.
    Loscalzo J; Pasche B; Ouimet H; Freedman JE
    Thromb Haemost; 1995 Jul; 74(1):291-3. PubMed ID: 8578474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
    Dominguez M; Cacoub P; Garcia de la Torre I; Piette TJ; Salazar-Paramo M; Godeau P; Angleés-Cano E
    J Rheumatol; 2001 Feb; 28(2):302-8. PubMed ID: 11246666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation.
    Leaker MT; Brooker LA; Mitchell LG; Weitz JI; Superina R; Andrew ME
    Transplantation; 1995 Jul; 60(2):144-7. PubMed ID: 7624956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH; Diamond SL
    J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.